Premium
Reslizumab: add‐on therapy for severe eosinophilic asthma
Author(s) -
Chaplin Steve
Publication year - 2017
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1553
Subject(s) - medicine , eosinophilic , asthma , dermatology , immunology , pathology
Resilzumab (Cinqaero) is a new add‐on therapy for severe inadequately controlled eosinophilic asthma, which is administered by monthly IV infusion. This article summarises its indications, efficacy and adverse effects.